Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.86 |
| ▸ | THRB | P10828 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19665219 | 0.84 | RXFP1 (0.64) | RXFP1THRBLMNAADORA2AADORA1 | |
| SCHEMBL3277717 | 0.82 | CA1 (0.68) | RXFP1THRBLMNAADORA2AADORA1 | |
| SCHEMBL6218562 | 0.77 | KMT2A (0.76) | RXFP1THRBLMNAADORA2AADORA1 | |
| SCHEMBL3285107 | 0.77 | LMNA (0.54) | RXFP1THRBLMNA | |
| SCHEMBL1060600 | 0.76 | RXFP1 (0.53) | RXFP1THRBLMNACA1CA2 | |
| SCHEMBL5257876 | 0.72 | KDM4E (0.54) | RXFP1THRBLMNACA1CA2 | |
| SCHEMBL1940331 | 0.71 | LMNA (0.73) | RXFP1THRBLMNACA1CA2 | |
| SCHEMBL2716692 | 0.70 | RXFP1 (0.55) | RXFP1THRBLMNACA1CA2 | |
| SCHEMBL2717013 | 0.69 | CA1 (0.69) | RXFP1THRBLMNACA1CA2 | |
| SCHEMBL2729885 | 0.69 | RXFP1 (0.70) | RXFP1THRBLMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700768-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7629462-B2 | Tetrasubstituted pyrimidine compounds as chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090048442-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20070238743-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2007-10-11 | — | — | US | disclosed |
| EP-1842851-A2 | Novel compounds | Smithkline Beecham Corporation (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070167467-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-7235551-B2 | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1265900-B1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO 4,5-D|PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1265900-A4 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO 4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20030100756-A1 | 1,5- disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | GLAXOSMITHKLINE LLC | 2003-05-29 | — | — | US | disclosed |
| EP-1265900-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO 4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SmithKline Beecham Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001064679-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100756-A1 | 1,5- disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | MAPKAPK2, MAPK4, MAP4K2 | RXFP1 3268/4885THRB 1818/4885LMNA 3558/4885 |
| US-20070167467-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | MAPKAPK2, CREBBP, CNBP | RXFP1 3565/4885THRB 1442/4885LMNA 3202/4885 |
| US-20070238743-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | MAPKAPK2, CREBBP, CNBP | RXFP1 3565/4885THRB 1442/4885LMNA 3202/4885 |
| US-20090048442-A1 | Novel compounds | CREBBP, MAPKAPK2, CNBP | RXFP1 3602/4885THRB 1162/4885LMNA 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.